JP6977185B2 - ピロリジン化合物の結晶 - Google Patents

ピロリジン化合物の結晶 Download PDF

Info

Publication number
JP6977185B2
JP6977185B2 JP2020562542A JP2020562542A JP6977185B2 JP 6977185 B2 JP6977185 B2 JP 6977185B2 JP 2020562542 A JP2020562542 A JP 2020562542A JP 2020562542 A JP2020562542 A JP 2020562542A JP 6977185 B2 JP6977185 B2 JP 6977185B2
Authority
JP
Japan
Prior art keywords
crystal
crystals
pyrrolidine
added
phosphoric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020562542A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020138481A1 (ja
Inventor
直子 上田
裕臣 長田
琢紘 吉田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JPWO2020138481A1 publication Critical patent/JPWO2020138481A1/ja
Priority to JP2021183553A priority Critical patent/JP7652682B2/ja
Application granted granted Critical
Publication of JP6977185B2 publication Critical patent/JP6977185B2/ja
Priority to JP2025041552A priority patent/JP2025085744A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020562542A 2018-12-28 2019-12-27 ピロリジン化合物の結晶 Active JP6977185B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021183553A JP7652682B2 (ja) 2018-12-28 2021-11-10 ピロリジン化合物の結晶
JP2025041552A JP2025085744A (ja) 2018-12-28 2025-03-14 ピロリジン化合物の結晶

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018247437 2018-12-28
JP2018247437 2018-12-28
PCT/JP2019/051570 WO2020138481A1 (ja) 2018-12-28 2019-12-27 ピロリジン化合物の結晶

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021183553A Division JP7652682B2 (ja) 2018-12-28 2021-11-10 ピロリジン化合物の結晶

Publications (2)

Publication Number Publication Date
JPWO2020138481A1 JPWO2020138481A1 (ja) 2021-09-27
JP6977185B2 true JP6977185B2 (ja) 2021-12-08

Family

ID=71127176

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020562542A Active JP6977185B2 (ja) 2018-12-28 2019-12-27 ピロリジン化合物の結晶
JP2021183553A Active JP7652682B2 (ja) 2018-12-28 2021-11-10 ピロリジン化合物の結晶
JP2025041552A Pending JP2025085744A (ja) 2018-12-28 2025-03-14 ピロリジン化合物の結晶

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021183553A Active JP7652682B2 (ja) 2018-12-28 2021-11-10 ピロリジン化合物の結晶
JP2025041552A Pending JP2025085744A (ja) 2018-12-28 2025-03-14 ピロリジン化合物の結晶

Country Status (8)

Country Link
US (2) US12077524B2 (enExample)
EP (4) EP3903785B1 (enExample)
JP (3) JP6977185B2 (enExample)
CN (3) CN120081826A (enExample)
ES (1) ES2991904T3 (enExample)
MA (1) MA54619A (enExample)
TW (3) TWI834791B (enExample)
WO (1) WO2020138481A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122595A1 (es) 2020-06-10 2022-09-21 Mitsubishi Tanabe Pharma Corp Agente profiláctico o terapéutico para fotodermatosis
KR102952931B1 (ko) 2020-06-10 2026-04-15 다나베 파마 가부시키가이샤 포르피린증의 예방 또는 치료제
CN122557552A (zh) * 2020-06-10 2026-08-14 田边制药株式会社 卟啉症的预防或治疗剂
CN117255786A (zh) * 2021-05-06 2023-12-19 株式会社Lg 化学 黑皮质素受体激动剂化合物的晶型vii及其制备方法
KR102854595B1 (ko) * 2021-05-06 2025-09-03 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법
KR102854598B1 (ko) * 2021-05-07 2025-09-03 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 황산염의 결정형 및 이의 제조방법
JP2024517271A (ja) * 2021-05-07 2024-04-19 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の有機酸塩の結晶形ｉｖおよびその製造方法
US20240239769A1 (en) * 2021-05-07 2024-07-18 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
KR20240145490A (ko) 2022-01-31 2024-10-07 미쓰비시 타나베 파마 코퍼레이션 멜라노코르틴 1 수용체 아고니스트의 신규 용도
WO2024029599A1 (ja) 2022-08-03 2024-02-08 田辺三菱製薬株式会社 １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP1951286A4 (en) * 2005-10-07 2009-11-04 Waratah Pharmaceuticals Inc COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS
PT3150578T (pt) * 2014-05-29 2021-01-18 Mitsubishi Tanabe Pharma Corp Novo composto de pirrolidina e aplicação como agonista do recetor de melanocortina
JP6392297B2 (ja) * 2015-11-27 2018-09-19 田辺三菱製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
ES2991904T3 (es) 2024-12-05
TWI919623B (zh) 2026-03-21
MA54619A (fr) 2021-11-03
CN120081827A (zh) 2025-06-03
JP2025085744A (ja) 2025-06-05
WO2020138481A1 (ja) 2020-07-02
JP7652682B2 (ja) 2025-03-27
EP3903785A4 (en) 2022-08-10
EP4603143A3 (en) 2025-11-05
EP4603143A2 (en) 2025-08-20
EP3903785A1 (en) 2021-11-03
TWI870228B (zh) 2025-01-11
TW202039464A (zh) 2020-11-01
CN113226314A (zh) 2021-08-06
TW202421621A (zh) 2024-06-01
JPWO2020138481A1 (ja) 2021-09-27
CN120081826A (zh) 2025-06-03
EP3903785B1 (en) 2024-10-02
EP4434582A3 (en) 2024-12-18
US12077524B2 (en) 2024-09-03
TW202517631A (zh) 2025-05-01
JP2022024034A (ja) 2022-02-08
TWI834791B (zh) 2024-03-11
EP4434582A2 (en) 2024-09-25
US20250002474A1 (en) 2025-01-02
CN113226314B (zh) 2025-03-18
EP4763282A2 (en) 2026-06-24
US20220073497A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
JP2022024034A (ja) ピロリジン化合物の結晶
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
CA2963581C (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
CN114437076B (zh) 一种酮咯酸与异烟肼共晶及其制备方法
CN114380833A (zh) 一种酮咯酸与4-吡啶甲酰胺共晶及其制备方法
AU2016318700A1 (en) Crystalline form of androgen receptor inhibitor and preparation method thereof
JP6761564B2 (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
EP2085397A1 (en) Crystalline form of abacavir
JP6985137B2 (ja) スルホンアミド化合物の結晶形
HK40130190A (en) Crystal of pyrrolidine compound
CN109422723B (zh) 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法
CN116178277A (zh) 氯比普兰甲磺酸盐晶型及其制备方法
EP3740587A1 (en) Fasoracetam crystalline forms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210702

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211012

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211110

R150 Certificate of patent or registration of utility model

Ref document number: 6977185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250